An Innovative Cardiac Ablation System for treating cardiac arrhythmias
Developing the next generation of Pulsed Field Ablation and Irreversible Electroporation
Venture-capital backed company
The challenge
Despite the technological advancements in cardiac ablation, the outcomes have only marginally improved in the past 15 years.
RF and Cryo are the most commonly used sources of energy used for cardiac ablation in the treatment of atrial fibrillation, Atrial-Flutter, and all other Arrhythmias.
Despite the development of these technologies and increased market adoption, long-term success remains in the range of 50-70% depending on the patient population.
- RF and Cryo are also associated with adverse events from the use of thermal energies as thermal energy destroys tissue indiscriminately increasing the risk of collateral injuries, such as oesophageal fistulas, pulmonary vein stenosis, and phrenic nerve palsy.
- The use of thermal energy may increase the difficulty to ensure the correct dose of therapy is delivered.
The market requires a technology that is safer, faster, and more efficient. It requires a solution that can create long-lasting outcomes.
Argá's solution
Argá Medtech is developing the next-generation non-thermal cardiac ablation system.
Its unique Pulsed Field Ablation (PFA) power generator offers unmatched flexibility when used with its proprietary catheter.
Argá develops a new PFA platform called Coherent Sine-burst Electroporation (CSE) that offers improved flexibility in titrating lesion depth and securing transmurality of lesions. Its catheter offers the practicality of single-shot device without losing its capability to produce linear and focal lesions, eliminating the need for catheter exchanges during procedures.
There's much more to success in cardiac ablation than to have just a better catheter design or a better energy delivery generator.
Improving cardiac ablation outcomes requires both.
